✦ LIBER ✦

Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: A review of the literature

✍ Scribed by Christophe Le Tourneau; Albiruni R.A. Razak; Hui K. Gan; Simona Pop; Véronique Diéras; Patricia Tresca; Xavier Paoletti

Book ID: 116430714
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 159 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2011.03.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

363 Dose of the molecularly targeted age

363 Dose of the molecularly targeted agents (MTA) in Phase 1 trials correlates with clinical benefit

✍ S. Gupta; A. Alqwasmi; S. Hunsberger; L. Rubinstein; P. Ivy; R. Royds; P. LoRuss 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 46 KB

A review of dose-limiting events in phas

A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity

✍ Lesley Seymour; Elizabeth Eisenhauer 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 115 KB

The Role of Age on Dose-Limiting Toxicit

The Role of Age on Dose-Limiting Toxicities in Phase I Dose-Escalation Trials

✍ Schwandt, A.; Harris, P. J.; Hunsberger, S.; Deleporte, A.; Smith, G. L.; Vulih, 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 331 KB

Estimating the Probability of Toxicity a

Estimating the Probability of Toxicity at the Recommended Dose Following a Phase I Clinical Trial in Cancer

✍ John O'Quigley 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 810 KB

1260 POSTER Preliminary Signs of Efficac

1260 POSTER Preliminary Signs of Efficacy Reported in Monotherapy Phase I Cancer Clinical Trials of Molecularly Targeted Agents and Correlation With Further Clinical Development

✍ J. Arrondeau; X. Paoletti; S. Pop; P. Tresca; V. Dieras; C. Le Tourneau 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 61 KB

1232 POSTER Creatinine Clearance (CrCI)

1232 POSTER Creatinine Clearance (CrCI) as a Predictive Marker for the Risk of Toxicity From Molecularly Targeted Agents (MTA) in Phase I Trials

✍ J. Vitfell-Pedersen; B. Basu; V. Moreno; A. Tjokrowidjaja; M. Puglisi; K. Shah; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 46 KB